Fig. 10

CB65 maintains the pluripotency of hiPSCs. CB65 slightly increases (A) OCT4- TRA-1-60 and (B) SOX2-SSEA4 double immune distribution of hiPSCs by FCM. (C) OCT4- TRA-1-60 presents a higher ratio in CB65 applied hiPSCs groups compared to vehicle (%0.001 DMSO) and CB65 + AM630 applied groups. * p < 0.05